Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial.

dc.contributor.author

Baumgartner, Iris

dc.contributor.author

Norgren, Lars

dc.contributor.author

Fowkes, F Gerry R

dc.contributor.author

Mulder, Hillary

dc.contributor.author

Patel, Manesh R

dc.contributor.author

Berger, Jeffrey S

dc.contributor.author

Jones, W Schuyler

dc.contributor.author

Rockhold, Frank W

dc.contributor.author

Katona, Brian G

dc.contributor.author

Mahaffey, Kenneth

dc.contributor.author

Hiatt, William R

dc.contributor.author

Executive Committee and Investigators of the EUCLID Trial

dc.date.accessioned

2019-10-14T21:09:02Z

dc.date.available

2019-10-14T21:09:02Z

dc.date.issued

2018-10

dc.date.updated

2019-10-14T21:09:01Z

dc.description.abstract

BACKGROUND:Lower extremity revascularization (LER) is a common treatment in patients with peripheral artery disease (PAD), but long-term outcomes are poorly defined. OBJECTIVES:The aim was to analyze LER in the EUCLID (Examining Use of tiCagreLor In paD) trial to determine predictors and cardiovascular outcomes. METHODS:Patients were grouped according to whether they received a post-randomization LER (n = 1,738) or not (n = 12,147). All variables were assessed for significance in univariable and parsimonious multivariable models. The primary endpoint was myocardial infarction, ischemic stroke, or cardiovascular death; major adverse limb events (MALE) included acute limb ischemia or major amputation. RESULTS:A post-randomization LER occurred in 12.5% of patients and was an endovascular LER in 74.7%. Endovascular LERs were performed more often in North America, whereas surgical procedures occurred more frequently in Europe. Independent factors predicting LER were prior and type of prior LER, geographic region, limb symptoms, diabetes, and smoking. A post-randomization LER was associated with an increased risk for the primary endpoint (hazard ratio: 1.60; 95% confidence interval: 1.35 to 1.90; p < 0.0001) and MALE (hazard ratio: 12.0; 95% confidence interval: 9.47 to 15.30; p < 0.0001). Event rates for the primary endpoint after LER were numerically higher in the surgical subgroup, but MALE were similar between surgical and endovascular LER. CONCLUSIONS:In the EUCLID trial, LER was most often endovascular. Following LER, there was an increased hazard for the primary endpoint (with higher event rates in the surgical group) and a markedly increased risk for MALE events (with similar event rates between surgical and endovascular LER procedures). (A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).

dc.identifier

S0735-1097(18)35749-8

dc.identifier.issn

0735-1097

dc.identifier.issn

1558-3597

dc.identifier.uri

https://hdl.handle.net/10161/19419

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Journal of the American College of Cardiology

dc.relation.isversionof

10.1016/j.jacc.2018.07.046

dc.subject

Executive Committee and Investigators of the EUCLID Trial

dc.subject

Lower Extremity

dc.subject

Femoral Artery

dc.subject

Popliteal Artery

dc.subject

Humans

dc.subject

Myocardial Infarction

dc.subject

Ischemia

dc.subject

Hemorrhage

dc.subject

Blood Vessel Prosthesis Implantation

dc.subject

Endarterectomy

dc.subject

Amputation

dc.subject

Aged

dc.subject

Female

dc.subject

Male

dc.subject

Stroke

dc.subject

Endovascular Procedures

dc.subject

Peripheral Arterial Disease

dc.title

Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial.

dc.type

Journal article

duke.contributor.orcid

Mulder, Hillary|0000-0003-4838-582X

duke.contributor.orcid

Patel, Manesh R|0000-0001-6477-9728

duke.contributor.orcid

Jones, W Schuyler|0000-0002-7288-9596

duke.contributor.orcid

Rockhold, Frank W|0000-0003-3732-4765

pubs.begin-page

1563

pubs.end-page

1572

pubs.issue

14

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Population Health Sciences

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Medicine, Cardiology

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke Innovation & Entrepreneurship

pubs.organisational-group

Initiatives

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.publication-status

Published

pubs.volume

72

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S0735109718357498-main.pdf
Size:
284.77 KB
Format:
Adobe Portable Document Format